| Business Summary | | The
Medicines
Company
acquires,
develops
and
commercializes
biopharmaceutical
products
that
are
in
late
stages
of
development
or
have
been
approved
for
marketing.
In
December
2000,
the
Company
received
marketing
approval
from
the
United
States
Food
and
Drug
Administration
(FDA)
for
Angiomax,
its
lead
product,
for
use
as
an
anticoagulant
in
combination
with
aspirin
in
patients
with
unstable
angina
undergoing
coronary
balloon
angioplasty.
The
Company
is
also
developing
Angiomax
for
additional
potential
applications
for
use
in
the
treatment
of
ischemic
heart
disease,
a
condition
that
occurs
when
organs
receive
an
inadequate
supply
of
oxygen
as
a
result
of
decreased
blood
flow.
To
date,
clinical
investigators
have
administered
Angiomax
to
approximately
12,600
patients
in
clinical
trials
in
the
treatment
and
prevention
of
blood
clots
in
a
wide
range
of
hospital
applications.
The
Company
believes
that
Angiomax
will
become
the
leading
replacement
for
heparin
in
hospital
care. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | The
Medicines
Company
acquires,
develops
and
commercializes
biopharmaceutical
products
in
the
late
stages
of
development.
For
the
six
months
ended
6/30/01,
revenues
totaled
$4
million,
up
from
$0.
Net
loss
applicable
to
Common
decreased
49%
to
$35
million.
Revenues
reflect
the
launch
of
the
Company's
lead
product,
Angiomax.
Lower
loss
reflects
the
absence
of
a
$19.4
million
interest
expense
and
a
$28.7
million
preferred
stock
dividend. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Clive Meanwell, M.D., Ph.D., 43 Pres,
CEO, Director | $335K | -- | Peyton Marshall, Ph.D., 45 Sr.
VP, CFO | 270K | -- | Glenn Sblendorio, 44 Sr.
VP | -- | -- | David Stack, 49 Sr.
VP | -- | -- | John Nystrom, Ph.D., 55 VP,
CTO | 215K | $348K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|